Novo to partner with Anthropic on drug discovery efforts

Read the original at Semafor ↗
Semafor · collected 2026-09-17 · by Brendan Ruberry

Quick Summary

Danish pharmaceutical company Novo Nordisk plans to collaborate with Anthropic to enhance its drug discovery processes through artificial intelligence technology. This move comes as Novo Nordisk seeks to regain market share it has lost in recent months, evidenced by a 20% drop in its stock prices over the past year. While other competitors like Lilly, Merck, and Roche have also invested in AI for productivity improvements and clinical trial design, Novo Nordisk aims to be at the forefront of using AI directly in discovering new drugs. The company is rebranding itself as simply "Novo" starting this week as part of its broader strategic shift.
Written locally by qwen2.5:14b on 2026-09-18, using this article's own text rather than the other coverage of the same event (that is the story summary below).

AI analysis runs on qwen2.5:14b, locally

Story summary

Danish drugmaker Novo Nordisk announced it will partner with AI research company Anthropic to accelerate its drug development efforts. This move comes after the company's stock price fell by 20% over the past year, amid competition from rivals such as Lilly, Merck, and Roche, which have also invested in artificial intelligence but primarily for improving workplace efficiency and clinical trial design rather than discovering new drugs. Novo Nordisk hopes that AI will aid in bioscience research and help it regain its market position lost to competitors, particularly since its Ozempic injectable became synonymous with GLP-1 treatments. To adapt to these changes, the company has also initiated a cultural shift within its organization.

Written for “Novo And Anthropic Partnership” on 2026-09-18, grounded in this article and the 0 other(s) covering the same event.
Why this leaning score
This article does not take a side on a contested political question, so it has no leaning score. That is an answer rather than a gap: a match report or a rescue can be warmly or critically written without being left or right, and scoring it anyway is how approval of a subject gets recorded as a political position.
No political leaning scored for article 17328 · logged 2026-09-18

Signals How these are calculated →

Claims extracted
3
claim-shaped sentences
Uncertain
0%
0 of 3 hedged
Leaning
not political
takes no side on a contested political question
Correction & hedging signals
94.7
corrections and hedging in what we collected; not a measure of accuracy
Outlets on this story
1
Technology
Narrative spread
1
articles carrying this framing
Analyzed 2026-09-18 · how these are computed

Story

📰 Novo And Anthropic Partnership
Technology · 1 article(s) covering the same event.

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Compared with similar articles

This article reads unscored and hedges 0% of its claims. Each row says how that neighbour differs.
CBS News
⚖️ Leans left 🔴 11% hedged 4 of 37 📰 publisher trust 71
“The articles describe different events related to Anthropic but occurring on distinct dates and involving separate topics: one is about Amodei's comments on AI risks, while the other is about a partnership with Novo Nordisk for drug discovery.”
Times of India
⚖️ leaning not scored 🔴 9% hedged 3 of 34 📰 publisher trust 94
“The articles describe different events: one about an eighth-grade student's research project using AI to screen molecules for treating frontotemporal dementia, and another about a pharmaceutical company partnering with Anthropic to use AI in drug discovery efforts.”

Publisher

Semafor · 392 article(s) · 0 correction(s) detected
No corrections detected for this publisher. That may mean careful reporting, or simply that nothing has been checked.

Who wrote this

Brendan Ruberry
48 article(s) here · 1 carrying a prediction
🔮 Though Warsh reiterated the central bank’s independence Wednesday, Trump later revealed that he spoke to him before the Fed’s meeting, suggesting Warsh may have been “trying to foam the runway,” a Wall Street Journal columnist wrote.
2026-09-17 · assertive framing · Trump backs Fed's Warsh following rate hike
🔮 Danish drugmaker Novo Nordisk will partner with Anthropic in an effort to speed up drug development, as the one-time GLP-1 leader bets AI will help it reclaim lost market share.
🔮 American automaker General Motors will manufacture components for Patriot missiles, Lockheed Martin announced Thursday, potentially boosting efforts to plug the US’ gaping munitions holes that have emerged during more than six months of conflict with Iran.
2026-09-17 · assertive framing · GM to build Patriot missile parts for Lockheed Martin
🔮 US President Donald Trump will reportedly greet China’s leader Xi Jinping as he steps off the plane in Washington, DC next week — the first leader accorded that deference in Trump’s second term — as preparations ramp up for their summit.
2026-09-17 · speculative framing · US, China ramp up summit preparations
🔮 China has helped keep oil prices in 2026 down by slashing its imports, but Beijing is “coming back off its crash diet,” an energy analyst said, raising fears that prices could surge if fighting between Saudi Arabia and Yemen’s Houthis continues to disrupt supply.
2026-09-17 · mixed framing · Chinese oil prices hit record high
🔮 Still, strong retail and employment figures suggested the economy could withstand higher interest rates, and AI-fueled profits are set to drive growth across every sector of the S&P 500 in the third quarter, Bloomberg Intelligence said.
🔮 Canada’s retaliatory tariffs against $27.6 billion worth of US goods will kick in after midnight on Tuesday, as the prospects for averting a tit-for-tat trade war appeared dim.
🔮 The nationalist AfD’s landslide victory in a German state on Sunday could portend a far-right surge across Europe, analysts argued.
2026-09-15 · assertive framing · AfD win could portend rightist surge across Europe
🔮 Malaysia is considering using Huawei chips to power its sovereign AI efforts, Bloomberg reported, in what would be the first known instance of a foreign government choosing Chinese accelerators over American ones.
2026-09-15 · speculative framing · Malaysia eyes Huawei chips despite US warnings
🔮 “It’s a good bet that AI will eventually make some occupations obsolete,” but so far it’s “extremely hard” to identify any, the economist Noah Smith wrote, suggesting that like previous technological revolutions AI could add as many or even more jobs than it destroys.
2026-09-15 · mixed framing · AI is not yet driving US job losses
More on this subject from Brendan Ruberry
AI slowdown calls prompt chip selloff
2026-09-14 · Semafor · 52% similar
All 48 articles by Brendan Ruberry →

Topics

Anthropic Danish Lilly Novo Novo Nordisk

Subjects

Novo ORG · 3× Novo Nordisk ORG · 2× Anthropic ORG · 1× Danish NORP · 1× Lilly ORG · 1× Merck ORG · 1× Roche ORG · 1×

Narrative

Novo rivals Lilly, Merck, and Roche have all invested in AI, though it has largely been used to improve workplace productivity and design clinical trials, rather than discover new drugs. But researchers are bullish on AI’s use for bioscience, and Novo — having jumped out to a lead with its Ozempic injectable that became synonymous with GLP-1s — is playing catch up: Its shares have plunged 20% in the past year, prompting the firm to launch a culture shake-up.
framing: assertive · carried by 1 article(s) · first seen 2026-09-18
🔮 Danish drugmaker Novo Nordisk will partner with Anthropic in an effort to speed up drug development, as the one-time GLP-1 leader bets AI will help it reclaim lost market share.
2026-09-18 · Semafor
Novo to partner with Anthropic on drug discovery efforts · assertive framing

Claims (3 extracted, 0 hedged)

Danish drugmaker Novo Nordisk will partner with Anthropic in an effort to speed up drug development, as the one-time GLP-1 leader bets AI will help it reclaim lost market share. asserted
it → partner → share
Novo rivals Lilly, Merck, and Roche have all invested in AI, though it has largely been used to improve workplace productivity and design clinical trials, rather than discover new drugs. But researchers are bullish on AI’s use for bioscience, and Novo — having jumped out to a lead with its Ozempic injectable that became synonymous with GLP-1s — is playing catch up: Its shares have plunged 20% in the past year, prompting the firm to launch a culture shake-up. asserted
shares → invest → up
From this week, Novo Nordisk will henceforth be known simply as “Novo.” asserted
Nordisk → know → Novo
💬 Give feedback
🕘 History 🎫 Support